Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences.
Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs)
Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs)
Life sciences talent and strategic consultancy, RBW Consulting, has today announced the opening of